New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
The Food and Drug Administration (FDA) is issuing final regulations under which the agency will accelerate approval of certain new drugs and biological products for serious or life-threatening illnesses, with provisions for any necessary continued study of the drugs' clinical benefits after approval or with restrictions on use, if necessary. These new procedures are intended to provide expedited marketing of drugs for patients suffering from such illnesses when the drugs provide meaningful therapeutic benefit compared to existing treatment. Accelerated approval will be considered in two situations: (1) When approval can be reliably based on evidence from adequate and well-controlled studies of the drug's effect on a surrogate endpoint that reasonably suggests clinical benefit or on evidence of the drug's effect on a clinical endpoint other than survival or irreversible morbidity, pending completion of studies to establish and define the degree of clinical benefits to patients; and (2) when FDA determines that a drug, effective for the treatment of a disease, can be used safely only if distribution or use is modified or restricted. Drugs or biological products approved under these procedures will have met the requisite standards for safety and effectiveness under the Federal Food, Drug and Cosmetic Act (the act) or the Public Health Service Act (the PHS Act) and, thus, will have full approval for marketing.
D000900:Anti-Bacterial Agents / Q000592:standards; D001688:Biological Products / Q000592:standards; D016638:Critical Illness; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational / Q000592:standards*; D035082:Federal Government; D033161:Government Regulation; D006801:Humans; D011358:Product Surveillance, Postmarketing / Q000592:standards; D018570:Risk Assessment; D036302:Therapeutic Human Experimentation; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration